{"id":"W4213066787","doi":"10.1200/jco.2022.40.6_suppl.tps284","title":"DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University; Ottawa Hospital; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Placebo; Internal medicine; Docetaxel; Randomization; Oncology; Randomized controlled trial; Antiandrogen; Tolerability; Urology; Cancer; Adverse effect; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002084733,0.001780207,0.002455167,0.0007672207,0.0004770528,0.001018451,0.001534834,0.002031664,0.008984044],"category_scores_gemma":[0.001535526,0.0007669806,0.001540416,0.0005834389,0.001475578,0.001000618,0.0005221755,0.003609187,0.001167173],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007279325,"about_ca_system_score_gemma":0.00190932,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001058265,"about_ca_topic_score_gemma":0.002353104,"domain_scores_codex":[0.999337,0.0003892158,0.00002823209,0.0001022726,0.0000505724,0.00009265865],"domain_scores_gemma":[0.9991357,0.0002138187,0.0001790556,0.00005836972,0.00004995265,0.0003632115],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9648089,0.01086109,0.000301925,0.0007838167,0.0006102327,0.00002947851,0.0000384164,0.0003146285,0.003383235,0.0001710514,0.001283262,0.01741389],"study_design_scores_gemma":[0.9296847,0.06827521,0.0005946616,0.00002170761,0.0001865919,0.00002350093,0.000009047524,0.0001868056,0.0004323997,0.00006772848,0.0005070999,0.00001050997],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.972967,0.009141223,0.0008298161,0.0008057971,0.0006980938,0.009013214,0.002062761,0.000402464,0.004079636],"genre_scores_gemma":[0.9738231,0.004476197,0.002640978,0.001402425,0.0004395755,0.01053288,0.00190145,0.000044321,0.00473898],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008984044,"threshold_uncertainty_score":0.03005469,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1202845928115184,"score_gpt":0.4689402118067739,"score_spread":0.3486556189952554,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}